EuropaBio, the European Association for Bioindustries, has begun publishing a Biomanufacturing Global Series. To date, EuropaBio has published the following one-page summaries, providing information on a country’s policies, targets, and investments:

• US in Focus: According to EuropaBio, the United States has a comprehensive approach, targeting challenges such as climate change or national security, and sectors, including chemical, agriculture, and health. EuropaBio states that the Biden Administration “considers biotechnology and biomanufacturing essential activities” to develop innovative solutions and foster the American bioeconomy, expanding their potential to contribute to challenges such as climate and energy goals, food sustainability, and supply chain security.
• India in Focus: EuropaBio states that the National Biotechnology Development Strategy, last updated in 2020, describes biotechnology as a key tool for national development and societal well-being and that its main mission is to ensure India’s global competitiveness throughout the dimensions of biotechnology, research and innovation, entrepreneurship, and industrial growth. Like the United States, India sees biotechnology strengthened in the wake of the COVID-19 pandemic. According to EuropaBio, India “identifies strengths such as its scientific human capital and cost-effective biomanufacturing capabilities and the need to focus and invest on enhancing [research and development (R&D)] expenditure, improving the link between research and commercialisation and ensuring the international quality standards.”
• Japan in Focus: EuropaBio states that according to the U.S. International Trade Administration, Japan designed its Bioeconomy Strategy 2019 to “develop and advance the biotech sector to realize ‘the world’s most advanced bioeconomy society by 2030.’” The Bioeconomy Strategy’s main points are expansion of the biobased market, formation of a bio community, and establishment of a data platform. According to EuropaBio, Japan plans to invest in biotechnology to expand its biobased market through biomanufacturing with biorefineries, primary production with gene editing technologies in agriculture, and healthcare with biopharmaceuticals and vaccines.